LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Elenco Azioni・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

18.54 0.87

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

18.12

Massimo

18.76

Metriche Chiave
By Trading Economics
Entrata	-607K -51M
Vendite	-28M 100M
EPS	-0.46
Margine di Profitto	-51.215
Dipendenti	1,784
EBITDA	4.1M -44M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+75.61% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-308M 2.1B
Apertura precedente	17.67
Chiusura precedente	18.54

Notizie sul Sentiment di mercato

By Acuity

30%

70%

59 / 344 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 mag 2026, 21:33 UTC

Utili

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mag 2026, 21:00 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mag 2026, 20:18 UTC

Utili

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mag 2026, 23:49 UTC

Discorsi di Mercato

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mag 2026, 23:39 UTC

Discorsi di Mercato

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mag 2026, 23:34 UTC

Discorsi di Mercato

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mag 2026, 23:34 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 mag 2026, 23:08 UTC

Discorsi di Mercato

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mag 2026, 22:21 UTC

Discorsi di Mercato

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mag 2026, 21:29 UTC

Azioni calde

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mag 2026, 21:08 UTC

Utili

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mag 2026, 21:02 UTC

Utili

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mag 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mag 2026, 20:55 UTC

Utili

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 mag 2026, 20:48 UTC

Utili

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mag 2026, 20:45 UTC

Utili

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mag 2026, 20:34 UTC

Acquisizioni, Fusioni, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 mag 2026, 20:32 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mag 2026, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mag 2026, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mag 2026, 20:30 UTC

Utili

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mag 2026, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mag 2026, 20:22 UTC

Utili

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mag 2026, 20:16 UTC

Utili

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mag 2026, 20:13 UTC

Utili

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mag 2026, 20:13 UTC

Utili

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mag 2026, 20:13 UTC

Utili

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mag 2026, 20:12 UTC

Utili

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mag 2026, 20:12 UTC

Utili

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

75.61% in crescita

Previsioni per 12 mesi

Media 32.4 USD 75.61%

Alto 44 USD

Basso 21.6 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

59 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.